Naphthalene

Naphthalene

SCHEMBL6005433

O=Cc1ccccc1.c1ccc2ccccc2c1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.82
CYP2A6 P11509 3/20 0.82
ALOX12 P18054 1/20 0.47
RELA Q04206 1/20 0.46
LMNA P02545 2/20 0.46
TRPA1 O75762 1/20 0.46
ALOX5 P09917 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
TYR P14679 1/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 1/20 0.43
ALDH5A1 P51649 1/20 0.43
ABAT P80404 1/20 0.43
UNG P13051 1/20 0.43
MEN1 O00255 1/20 0.43
THRB P10828 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PPARG P37231 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzaldehyde SCHEMBL10051945 0.91
Benzaldehyde SCHEMBL1330097 0.91
Benzaldehyde SCHEMBL22400699 0.91 ALDH1A1 (1.00) ALDH1A1CYP2A6LMNATRPA1ALOX5
Benzaldehyde SCHEMBL573 0.91
Benzaldehyde SCHEMBL896024 0.91 ALDH1A1 (1.00) ALDH1A1CYP2A6LMNATRPA1ALOX5
Benzaldehyde SCHEMBL6061133 0.91 ALDH1A1 (1.00) ALDH1A1CYP2A6LMNATRPA1ALOX5
Benzaldehyde SCHEMBL9236967 0.91
Benzaldehyde SCHEMBL715926 0.88 ALDH1A1 (0.93) ALDH1A1CYP2A6LMNATRPA1ALOX5
Benzaldehyde SCHEMBL1505090 0.88
Benzaldehyde SCHEMBL11784656 0.88 ALDH1A1 (0.93) ALDH1A1CYP2A6LMNATRPA1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105264440-B Anti-corrosion agent composition 三菱瓦斯化学株式会社 2019-09-24 CN disclosed
CN-110198924-A Compound, resin, composition and pattern forming method 三菱瓦斯化学株式会社 2019-09-03 CN disclosed
CN-110023276-A Compound, resin, composition and corrosion-resisting pattern forming method and circuit pattern forming method 三菱瓦斯化学株式会社 2019-07-16 CN disclosed
CN-110023277-A Compound, resin, composition and corrosion-resisting pattern forming method and circuit pattern forming method 三菱瓦斯化学株式会社 2019-07-16 CN disclosed
CN-109790097-A Compound, resin, composition and corrosion-resisting pattern forming method and circuit pattern forming method 三菱瓦斯化学株式会社 2019-05-21 CN disclosed
CN-109678895-A Mercaptopyridine resorcinol cup [4] aromatic hydrocarbons Zn complex and preparation method and application 东北师范大学 2019-04-26 CN disclosed
CN-104737073-B Anti-corrosion agent composition 三菱瓦斯化学株式会社 2019-03-08 CN disclosed
CN-104281006-B Radiation-ray sensitive composition 三菱瓦斯化学株式会社 2019-01-22 CN disclosed
CN-108264456-A The synthetic method and its synthetic intermediate that 2,8- dibromos are bent 湖北尚赛光电材料有限公司 2018-07-10 CN disclosed
CN-106085316-A Encapsulating epoxy resin composition and electronic part apparatus 日立化成工业株式会社 2016-11-09 CN disclosed
CN-102585438-A Epoxy resin composition for sealing and electronic component device HITACHI CHEMICAL CO LTD 2012-07-18 CN disclosed
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. 2006-12-21 US disclosed
EP-1014966-B1 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS ALLELIX NEUROSCIENCE INC (US) 2006-08-02 EP disclosed
US-7019024-B2 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. (US) 2006-03-28 US disclosed
EP-1014966-A4 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS ALLELIX NEUROSCIENCE INC (US) 2001-10-04 EP disclosed
US-20010012857-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders NPS PHARMACEUTICALS, INC. 2001-08-09 US disclosed
US-6191165-B1 ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS ALLELIX NEUROSCIENCE INC. 2001-02-20 US disclosed
EP-1014966-A1 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS Allelix Neuroscience Inc. (US) 2000-07-05 EP disclosed
WO-1997045115-A1 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS TROPHIX PHARMACEUTICALS, INC. (US) 1997-12-04 WO disclosed
US-4127595-A FROM A 1,4-DIHYDROANTHRAQUINONE WITH ACROLEIN OR PRECURSOR, DEHYDRATION CATALYST KAWASAKI KASEI CHEMICALS LTD. (JP) 1978-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders SLC18A2, SLC6A1, SLC6A11 ALDH1A1 806/4885CYP2A6 576/4885ALOX12 1632/4885
US-20010012857-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders SLC6A1, SLC18A2, SLC6A11 ALDH1A1 357/4885CYP2A6 531/4885ALOX12 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.